Baxalta submits sBLAs to FDA for approval of ADYNOVATE

Baxalta has submitted sBLAs to the FDA for its approval of ADYNOVATE
Baxalta has submitted sBLAs to the FDA for its approval of ADYNOVATE | morguefile.com
Baxalta Inc., a worldwide leader in pharmaceuticals committed to developing therapies to combat orphan diseases, recently announced the submission of supplemental Biologics License Applications (sBLAs) for the approval of ADYNOVATE by the U.S. Food and Drug Administration (FDA).

ADYNOVATE is designed to be used in surgery and for the treatment of children ages 12 and younger that have been diagnosed with hemophilia A.

ADYNOVATE was originally approved by the FDA in November of last year to treat both adult and adolescent patients with hemophilia to reduce bleeding episodes associated with prophylaxis. It is currently the only medicine with a prolonged circulating half-life recombinant Factor VIII (rFVIII) designed to treat hemophilia A.

Baxalta submitted the sBLAs for ADYNOVATE after successful results of a Phase 3 trial that assessed the safety and effectiveness of the drug. The data collected from the trial met its primary goals with none of the patients that took part developing inhibitory antibodies to the medication. There were also no side effects reported during the duration of the trial.

Baxalta is committed to further developing ADYNOVATE to help treat patients on a worldwide scale. The company is currently seeking approval for ADYNOVATE in Europe, Japan, Canada and Switzerland.
Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Baxalta, Inc. 1200 Lakeside Drive Bannockburn, IL 60015

U.S. Food and Drug Administration (FDA) 10903 New Hampshire Ave Silver Spring, MD 20903